Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SAR442501 in pediatric participants with Achondroplasia

Trial Identifier: DRI16646
Sponsor: Sanofi
Start Date: October 2023
Primary Completion Date: February 2025
Study Completion Date: February 2025
Condition: Osteochondrodysplasia

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Australia, Victoria PARKVILLE, Victoria, Australia, 3052
China SHANGHAI, China, 200120
China WUHAN, China, 430030
Italy, Lombardia MILAN, Lombardia, Italy, 20122
Italy, Roma ROME, Roma, Italy, 00168
ITALY, Roma Rome, Roma, ITALY, 00168
Korea, Republic of, Seoul-teukbyeolsi SEOUL, Seoul-teukbyeolsi, Korea, Republic of, 06351
Korea, Republic of, Seoul-teukbyeolsi SEOUL, Seoul-teukbyeolsi, Korea, Republic of, 03080
Spain, Catalunya [Cataluña] ESPLUGUES DE LLOBREGAT, Catalunya [Cataluña], Spain, 08950
Spain, Pais Vasco VITORIA-GASTEIZ, Pais Vasco, Spain, 01008